Background {#Sec1}
==========

Acute kidney injury (AKI) is a medical complication associated with significant morbidity and mortality in critically ill patients \[[@CR1]--[@CR3]\]. AKI is common in critical illness, and severe AKI is associated with up to 60 % hospital mortality \[[@CR4]\]. Renal replacement therapy (RRT) within the intensive care unit (ICU) is conducted as either intermittent hemodialysis or continuous renal replacement therapy (CRRT). Traditional indications for RRT require the development of overt clinical manifestations of renal insufficiency, such as acidosis, electrolyte disturbances (most notably hyperkalemia), uremic complications (encephalopathy or pericarditis), and volume overload unresponsive to aggressive medical management. In spite of research and increasing clinical experience with dialysis, the optimal time to initiate RRT in the course of critical illness complicated by AKI is unclear.

The notion of "early" RRT is to initiate dialysis therapy before nitrogenous and other metabolic products accumulate to the degree where they become relatively resistant to therapy \[[@CR5], [@CR6]\]. Despite the intuitive rationale for "early" RRT, there is limited evidence to guide clinicians on the optimal time to initiate RRT in critical illness. Neither standard clinical parameters nor research into novel clinical biomarkers has emerged to clearly define an ideal time or clinical picture where the initiation of RRT optimizes patient outcomes. Earlier initiation of RRT must be balanced with potential patient harm associated with RRTs. Protocolled use of hemofiltration for 96 h in patients with septic shock admitted to an ICU regardless of their renal function suggests that "early" RRT can be associated with negative patient outcomes \[[@CR7]\]. As a result, research into "early" RRT includes multiple definitions of *early* that reflect a potpourri of time factors, biochemical markers, and clinical parameters in an attempt to balance the risks of initiating RRT with the benefits expected from supporting renal function during critical illness.

The authors of two earlier meta-analyses pooled available data on this topic to suggest that "early" RRT improves survival in critical illness. Seabra et al. \[[@CR8]\] identified 23 studies (5 randomized controlled trials \[RCTs\]/quasi-RCTs, 1 prospective study, and 17 retrospective cohort studies) and concluded that "early" initiation of RRT was associated with 28 % mortality risk reduction (relative risk \[RR\] 0.72, 95 % CI 0.64--0.82, *p* \< 0.001). Karvellas et al. \[[@CR9]\] identified 15 studies (2 RCTs, 4 prospective studies, and 9 retrospective cohort studies) and reached similar conclusions, reporting a significant improvement in 28-day mortality with "early" RRT (OR 0.45, 95 % CI 0.28--0.72, *p* \< 0.001). However, the overall findings were not congruent with the subgroup analysis of randomized trials (RR 0.64, 95 % CI 0.4--1.05, *p* = 0.08), where there was a signal that "early" RRT was not associated with a significant survival advantage. This has diminished clinical confidence in the conclusions reached by the earlier meta-analyses, and consequently "early" RRT in critical illness remains a controversial therapeutic intervention.

Since 2012, additional studies have been published that do not support the conclusions of the previous meta-analyses, and this has further diminished the confidence in the previous conclusions that suggested a survival benefit in critical illness associated with "early" RRT. We conducted a systematic review and evidence synthesis to investigate whether "early" versus "late" initiation of RRT in critically ill patients with AKI improves patient survival and selected secondary outcomes for potential signals to suggest that "early" RRT may reduce patient morbidity or enhance illness recovery. Our goal was to identify the highest-quality studies on this topic and use a pooled meta-analysis of these studies to inform our conclusions.

Methods {#Sec2}
=======

Search strategy {#Sec3}
---------------

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@CR10]\] (see Additional file [1](#MOESM1){ref-type="media"}: Figure S1 for PRISMA checklist). Our null hypothesis was that "early" initiation of RRT does not improve patient survival in critical care patients with AKI. This systematic review was not registered, and a protocol does not exist. The PubMed and Embase databases were searched to identify published articles following four broad themes: AKI, RRT, time of initiation, and critical illness (see Additional file [2](#MOESM2){ref-type="media"}: Table S1 for search terms). SK is a National Institutes of Health (NIH) physician and requested the NIH librarian to provide oversight for the search strategy. Our search was limited to English-language-only, full-text primary research publications (including abstracts with full text availability) reporting findings of clinical trials and observational studies (cohort and case-control design) published between January 1985 and November 2015. Studies before 1985 were not actively sought, owing to a low likelihood of relevance to modern RRTs and critical care practices.

Study selection {#Sec4}
---------------

References were screened and excluded if they were small case reports or observational studies (fewer than 10 subjects), were not focused on critically ill adult patients, did not report mortality data, involved basic science data, or did not clearly distinguish between "early" and "late" groups. This task was divided among the authors. A second evaluation led by the senior author (RLCK) was conducted to evaluate study quality. Studies were designated as being of "high quality" or "low quality." Studies were assigned a "low-quality" rating if there was no illness severity assessment between cohorts or at the time of randomization (*n* = 8), significant differences (*p* \< 0.05) between cohort groups (*n* = 7) at baseline, incomplete basic demographic data at baseline (*n* = 6) to exclude baseline differences, or a Newcastle-Ottawa Quality Assessment (NOQA) Scale \[[@CR11]\] for cohort studies rating less than 7 (*n* = 6). The senior author (RLCK) was the arbiter in cases of disagreement. Only high-quality studies were included in quantitative meta-analysis of the primary and secondary outcomes.

Primary and secondary outcomes {#Sec5}
------------------------------

The primary outcome of interest was mortality at 1 month (pooling outcomes for mortality at 28 or 30 days, depending on what was reported by the primary authors). In addition to mortality, we analyzed selected secondary outcomes, including ICU length of stay (LOS) and hospital LOS. Secondary outcomes were not consistently reported for all studies, and only studies with applicable data were included in our pooled analysis. Weighted means were calculated as a product of the number of patients and mean duration to reach a total and represented as a total of patient-days per study. These values were summed and divided by the total number of patients from all included studies to reach weighted mean duration of LOS for both hospital and ICU LOS metrics. A similar process was used to derive the mean weighted illness severity scores. Other potentially relevant secondary outcomes, including mechanical ventilation requirements, vasopressor requirements, and renal recovery rates, were considered, but these variables were inconsistently reported and commonalities could not be reached among the heterogeneous parameters that were available.

Definition of "early" versus "late" {#Sec6}
-----------------------------------

*Early* was defined on the basis of criteria used by the original authors in their respective studies. We accepted a broad definition of *early* based on biochemical markers according to RIFLE classifications (risk, injury, failure, loss of function, and end-stage kidney disease), Acute Kidney Injury Network (AKIN) stages, or time-based cutoffs (e.g., within a defined time from ICU admission or development of a biochemical "start time"). Accepting a broad definition of *early* was intended to optimize the potential for identifying an effect associated with "early" RRT. A limitation of this approach is that "early" according to one study investigator might be considered "late" by another study investigator. "Late" RRT criteria involved either usual practice or expectant care (i.e., no RRT initiated). "Usual practice" generally involved implementing RRT following the development of classic RRT indications unresponsive to medical management.

Statistical analysis {#Sec7}
--------------------

The quality of cohort trials was assessed using the NOQA Scale (range from 0 to 9, with 9 indicating the highest quality) \[[@CR11]\]. The NOQA Scale for cohort studies assesses the domains of population selection, comparability of cohorts, and outcome assessment. A meta-analysis was conducted using the high-quality studies to calculate the pooled OR for mortality at 1 month. A random effects model was used because of the significant heterogeneity between studies on this topic. A random effects model is indicated when study populations differ in ways that could impact the results. Heterogeneity was assessed on the basis of the *Q* value and *I*^2^ and τ^2^ statistics. A *p* value less than 0.05 was considered statistically significant. All analyses were performed using Comprehensive Meta-Analysis version 3.3.070 software ([www.meta-analysis.com](http://www.meta-analysis.com/); Biostat, Englewood, NJ, USA).

Results {#Sec8}
=======

The systematic literature search yielded 2405 references that were subsequently refined to 36 studies eligible for inclusion in this meta-analysis (see Additional file [3](#MOESM3){ref-type="media"}: Figure S2 for article selection breakdown). These references included 7 RCTs \[[@CR7], [@CR12]--[@CR17]\], 10 prospective cohort studies \[[@CR18]--[@CR27]\], and 19 retrospective cohort studies \[[@CR28]--[@CR46]\]. Only nine studies met our criteria for high quality \[[@CR7], [@CR12], [@CR14]--[@CR17], [@CR21], [@CR35], [@CR40]\]. A summary of the fundamental characteristics of all evaluated studies is provided in Table [1](#Tab1){ref-type="table"}.Table 1Trial Summary Table by Study Type (*n*=36)Author, YearStudy DesignCountryDurationExclusionPatient PopulationPatients (n)Age (mean) yrsIllness Severity ScoreEarly RRT CriteriaLate RRT CriteriaStudy QualityPrimary OutcomeTotalEarly RRTLate RRTRandomized TrialsBouman, 2002 \[[@CR12]\]RCT, two-center studyNetherlandsMay 1998 - Mar 2000Pre-existing renal diseaseMultisystem1067036EHV: 68; ELV: 70; LLV: 67EHV: SOFA 10.3 - APACHE2=23.5, ELV: SOFA 10.1 - APACHE2=21.7; LLV: SOFA 10.6 - APACHE2=23.6TIME: Early \< 12 h (200ml); Early Low Vol \< 12 h (100-150ml)TIME: Late \> 12hHIGH28 d mortality: EHV: 9/35(26%) died, ELV: 11/35(31%) died, LLV: 9/36(25%) died; *p*=0.8Durmaz, 2003 \[[@CR13]\]RCTTurkeySept 1999 - Aug 2001Age\<18, chronic dialysisPost Cardiac Surgery442123Early 58; Late 54NRBIOCHEM: Cr rise \>10% from pre-op level within 48hrs of surgeryCr rise \>50% from pre-op level; or Urine output \<400ml/24hrs with coexistent K+/H+ unresponsive to med mgmtLOWHospital mortality: Early 1/21 (4.8%) died, Late 7/23 (30.4%) died *p*=0.048; Favors EarlySugahara, 2004 \[[@CR14]\]RCTJapanJan 1995 - Dec 1997Pregnancy, Bili \> 5mg/dL, Mental disorder, Cancer, Early recovery of urine output \>30ml/kg/hr prior to RRTPost Cardiac Surgery281414Early: 65; Late: 64Early: APACHE2=19; Late: APACHE2=18BIOCHEM: UOP \<30ml/hr × 3hrs OR UOP \<750ml/day; Mean time to RRT start 18d±0.9 post opUOP\<20ml/hr × 2hrs+ OR UOP \<500ml/day; Mean time to RRT start 1.7d±0.8 post opHIGH14 d mortality: Early 2/14 died (14%), Late 12/14 died (86%); *p*\<0.01 Favors EarlyPayen, 2009 \[[@CR7]\]RCT, multicenterFranceJan 1997 - Jan 2000Age\<18, chronic dialysis, pregnant, moribund state, prior immunosuppressive therapyMultisystem763739Early 58 Late 59Early: SOFA 11.6- SAPS2 54.3; Late: SOFA 10.4- SAPS2 52.4TIME: Protocolized RRT × 96hrs w/ diagnosis of 'sepsis'. Mean time to initiation of RRT not specifiedControl = No RRT unless metabolic renal failure & classic indications for RRT presentHIGHEarly 20/37 (54%) died, Late 17/37 (44%) died; *p* = 0.49Jamale, 2013 \[[@CR15]\]RCT, single centerIndiaApril 2010 - July 2012Required urgent dialysis at time of randomizationMultisystem208102106Early 43 Late 42Early: SOFA 7.3; Late: SOFA 8.2BIOCHEM: Cr \> 618μmol/LClassic indications for RRT, Symptomatic uremia unresponsive to med mgmtHIGHMortality: Early 21/102 (20.5%) died, Late 13/106 (12%); *p*=0.2Combes, 2015 \[[@CR16]\]RCT, multicenterUSA2009-2012\<18, Pregnant, Chronic RRT, Weight \>120kg, SAPS II\>90 (i.e. moribund)Post Cardiac Surgery224112112Early 61 Late 58Early: SOFA 11.5- SAPS2=54; Late: SOFA 12.0- SAPS2=55.1TIME: RRT initiated \<24hrs and continued for min of 48hrs; Mean time to randomization 12hrsClassic indications for RRT, Lifethreatening metabolic derangements unresponsive to med mgmtHIGHMortality: Early 40/112 (36%) died, Late 40/112 (36%) died; *p* = 1.0Wald, 2015 \[[@CR17]\]RCT, multicenterCanadaMay 2012 - Nov 2013Intoxication requiring RRT, Limited resuscitation directives, RRT within the previous 2 months, RPGN, Obstructive uropathy, \> 48hrs to doubling time of CrMultisystem1004852Early 62 Late 64Early: SOFA 13.3 Late: SOFA 12.8TIME: Time from randomization \< 12h; Mean time to RRT = 9.7hrsIntensivist judgement regarding hyperkalemia, volume overload, acidemia refractory to medical therapy, Uremic symptoms Mean time to RRT=32hrsHIGHMortality: Early 16/48 (33%) died, Late 19/52 died; *p* = 0.74RCT Totals786404382Pooled mortality: Early 120/404 (29.7%), Late 117/382 (30.6%); *n*=7Prospective TrialsLiu, 2006 \[[@CR18]\]Prospective Observational MulticentreMulti countriesFeb 1999 - Aug 2001GFR\<30ml/min/1.73m2Multisystem243122121Early 54 Late 58NRAzotemia defined by BUN\<76mg/dLAzotemia defined by BUN\>76mg/dLLOW NOQA=628 d mortality: Early 43/122(35%) died vs Late 50/121(41%) *P*=0.09 Favors EarlyIyem, 2009 \[[@CR19]\]Prospective Observational cohortTurkeyMay 2004 - April 2007Preexisting renal disease and pre operative high levels of urea and creatininePost cardiac surgery1859590Early: 64; Late: 62NRTIME: Evidence of 50% increase in BUN, low urine output (\<0.5mL/kg/h) triggering RRT started \< 48hrsTIME \> 48hrs to start of RRT for similar markers of renal failure managed medically for minimum 48hrsLOW NOQA=7In hosp mortality: Early 5/95(5%) died, Late 6/90(7%) died; NSBagshaw, 2009 \[[@CR20]\]Prospective Observational Multicentre (BEST Kidney)23 countriesSept 2000 - Dec 2001Pre existing chronic RRT, drug toxicity, age \<12Multisystem1227959268Early: 60, Delayed: 63, Late: 64; *p*=0.003Early: SOFA 10.9- SAPS2=53.5 Delayed: SOFA 11.1- SAPS2=46 Late: SOFA 10.7- SAPS2=43.1; *p*=0.04TIME: Early RRT started for azotemia (Urea\>30mmol/L or low urine output × 12h) \<2d (*n*=785), Delayed RRT started 2-5d (*n*=174) from ICU admissionRRT started \>5d from ICU admissionLOW NOQA=7Hosp mortality: Early 462/785(59%) died, Delayed 108/174(62%) died, Late 195/268(72%) died; *P*\<0.0011 Favors EarlyShiao, 2009 \[[@CR21]\]Prospective Observational MulticentreTaiwanJan 2002 - Dec2005Prior dialysis, without surgery, or surgery did not involve abdominal cavity. History of renal trasplantMajor abdominal surgery985147Early: 65; Late: 68Early: SOFA 8.3- APACHE2=18.2; Late: SOFA 8.5- APACHE2=18.8BIOCHEM: RIFLE criteria: RISK or pre-RISK criteria (Mean Time to RRT from ICU Admit = 7.3d)RIFLE criteria: INJURY or FAILURE criteria (Mean Time to RRT from ICU Admit=8.4d)HIGH NOQA=7Hosp mortality: Early 22/51(43%), Late35/47(75%); *p*=0.0028 Favors EarlySabater, 2009 \[[@CR22]\]Prospective ObservationalSpain2 yearsNRMultisystem14844104All patients mean = 60; NREarly: APACHE2=26; Late: APACHE2=24BIOCHEM: RRT initiated for RIFLE: RISK & INJURY; (Mean RRT start 2.2d post ICU admit)RRT initiated for RIFLE: FAILURE; (Mean RRT start 6.4d post ICU admit)LOW NOQA=7Mortality: Early 21/44 died, Late 68/104 died. *P*=0.047 Favors EarlyElseviers, 2010 \[[@CR23]\]Prospective Observational MulticentreBelgium2001-2005Pre existing renal disease (Cr\<1.5mg/dl), reduced kidney size on ultrasoundMultisystem1303653650Early 64; Late 67Early: SOFA 9.9- APACHE2=25.2; Late: SOFA 8.5- APACHE2=5.2, *p*=0.001BIOCHEM: Unspecified SHARF scoring criteria w/serum Cr \> 2mg/dLConservative approach = No RRTLOW NOQA=5Mortality: Early 379/653 (58%) died, Late 280/650 (43%) died; *p*\<0.001 Favors LateVaara, 2012 \[[@CR24]\]Prospective Observational Multicentre (FINNAKI Study)FinlandSep 2011 - Feb 2012NRSepsis, Cardiogenic Shock261NRNRNRSurvivors: SAPS2=47; Non-survivors: SAPS2=66TIME: Time\<24hrs from ICU admitTime\> 24hrs from ICU admitLOW NOQA=5OR for late 2.69 (1.07-6.73, *p*=0.035). Favors EarlyPerez, 2012 \[[@CR25]\]Prospective ObservationalSpainNRSepsis244135109Early 62; Late 62Early: SOFA 12; Late: SOFA 11TIME: Time from ICU admission to RRT \< 48hTIME \>48hrsLOW NOQA=590 d mortality: Early 71/135(53%) died, Late 78/109(72%) died; *p*=0.003. Favors EarlyLim, 2014 \[[@CR27]\]Single Centre Prospective CohortSingaporeDec 2010 - April 2013Chronic dialysis patients, Dialysis initiated prior to ICU admissionMedical & Surgical patients1408456Early 60; Late 64Early: SOFA 7; Late: SOFA 11; *p*=0.001BIOCHEM: AKIN stage 1 or 2 AND compelling indication or AKIN stage 3 (Cr≥354μmol/l or Cr\>300% baseline w/urine \<0.3cc/kg/h for 24h or anuria \>12h)Traditional indications: K\>6mmol/L, Urea ≥30mmol/L, pH\<7.25, Bicarb \<10mmol/L, Pulm edema, Uremic encephalopathy/pericarditisLOW NOQA=6Hosp mortality: Early 36/84(43%) died, Late 37/56(66%) died; *p*=0.007 Favors EarlyJun, 2014 \[[@CR26]\]Nested Observational, Multi-Centre Study 'RENAL' Study GroupNZ, AustraliaDec 2005 - Nov 2008Age\<18, Prior RRTduring admission, Prior RRT for CKDSepsis439219220Early 65; Late 64Early: SOFA: 2.0- APACHE3=107, Late: SOFA 2.1- APACHE3=100, *P*\<0.001TIME: AKI diagnosis to randomization \< 17.6 hrsTime from AKI diagnosis to randomization \>17.6hrsLOW NOQA=628 d mortality: Early 82/219(37%) died; Late 84/220(38%) died (*p*=0.923) NSPROSPECTIVE TOTALS428823621665Pooled mortality: Early 1229/2362 (52%), Late 833/1665 (50%); *n*=10Retrospective TrialsGettings, 1999 \[[@CR28]\]Retrospective cohortUSA1989 - 1997CRRT duration \<48hrs, Pediatric patients, Incomplete recordsTrauma1004159Early 40; Late 48Early ISS = 33.0; Late ISS = 37.2BIOCHEM: BUN \< 60mg/dL AND Oliguria, Vol overload, Electrolytes, Uremia; Mean RRT start post admission day 10; *p*\<0.0001BUN \> 60 mg/dL AND Oliguria, Vol overload, Electrolytes, Uremia; Mean RRT start post admission day 19LOW NOQA=5Hosp mortality: Early 25/41(61%) died, Late 47/59(80%) died; *p*=0.041 Favors EarlyElahi, 2004 \[[@CR29]\]Retrospective cohortUKJan 2002 - Jan 2003Preexisting renal diseasePost cardiac surgery643628Early 69; Late 68NRBIOCHEM: Low urine output = less than 100 ml within 8h after surgery;Mean RRT start 0.78 daysTraditional indications: Urea ≥30mmol/L, Cr Elahi, 2004 \[[@CR29]\] ≥250mmol/L, K \> 6.0mEq/L; Mean RRT start 2.5 daysLOW NOQA=628 d mortality: Early-8/36 died (22%), Late-12/28 (43%); *p*\<0.05 Favors EarlyDemirkilic, 2004 \[[@CR30]\]Retrospective cohortTurkeyMar 1992 - Sep 2001NRPost Cardiac Surgery613427NR p=0.3NRBIOCHEM: Low urine output = less than 100ml within 8hrs post op; Mean RRT start 0.88 daysCr≥5mg/dL, or K\>5.5 mEq/L w/med mgmt; Mar 92-Jun 96; Mean RRT start 2.56 daysLOW NOQA=6Hosp mortality: Early 8/34(23%), Late 15/27(56%); *P*=0.016 Favors EarlyWu, 2007 \[[@CR32]\]Retrospective cohortTaiwanJuly 2002- Jan2005Hepatorenal syndrome from cirrhosis, liver trasplant, cardiopolmunary resuccitationAcute liver failure805426Early 55; Late 63; p=0.03Early: SOFA 12.4- APACHE2=18.2; Late: SOFA 13.2- APACHE2=20.5BIOCHEM: BUN \< 80 mg/dL AND traditional indications presentTraditional indications present with BUN \> 80mg/dLLOW NOQA=630 d mortality: Early 34/54(63%) died vs Late 22/26(85%) died; *P*=0.04 Favors EarlyAndrade, 2007 \[[@CR31]\]Retrospective cohortBrazil2002-2005Patients who did not have both AKI and respiratory failure believed secondary to leptospirosisLeptospirosis331815Early 42; Late 44Early: APACHE2=24.5; Late: APACHE2=26TIME: Mean time to RRT = 265 minMean time to RRT = 1638 minLOW NOQA=5Hosp mortality: Early 3/18(17%) died, Late 10/15(67%) died; *P*=0.01 Favors EarlyManche, 2008 \[[@CR33]\]Retrospective cohortMalta1995-2006NRPost Cardiac Surgery715615Early 66; Late 63NRBIOCHEM: Urine output\<0.5ml/kg/hr unresponsive to med mgmt; Mean RRT start 8.6hrs post-opOliguria (output \< 0.5ml/Kg/hr) refractory to med mgmt; Mean RRT start 41.2hrs post-opLOW NOQA=6Mortality: Early 14/56(25%) died, Late 13/15(87%) died; *P*=0.0000125 Favors EarlyLundy, 2009 \[[@CR34]\]Retrospective cohortUSNov 2005 - Aug 2007Preexisting renal disease, burn size of less than 40% Non-thermal injury, lithium toxicitySevere Burned patients572928Early 27; Late 38 P=0.06Early: SOFA 13- APACHE2=35; Late: SOFA 13- APACHE2=36BIOCHEM: AKIN stage 2(+shock)/3; Mean time from admit to RRT = 17 daysMean time from admit to AKIN stage 2(+shock)/3 but not dialyzed = 23 daysLOW NOQA=628 d mortality: Early 9/29(31%) died, Late 24/28(85%) died; *P*\<0.002; Favors EarlyCarl, 2010 \[[@CR35]\]Retrospective cohortUS2000-2004Baseline eGF0R \<30ml/min, Age \<18 & prisonersSepsis1478562Early 52; Late 56Early: APACHE2=24.8; Late: APACHE2=24.7BIOCHEM: BUN \<100mg/dL + AKIN stage \>2; Mean ICU stay prior to RRT =6.3daysBUN \> 100mg/dL + AKIN stage \>2; Mean ICU stay prior to RRT=12.3daysHIGH NOQA=728 d mortality: Early 44/85(52%) died, Late 42/62(68%); *P*\<0.05 Favors EarlyChou, 2011 \[[@CR37]\]Retrospective cohort 'NSARF' databaseTaiwanJan 2002 - Oct 2009Age\< 18, ICU stay \<2days, RRT \< 2daysSepsis + AKI370192178Early 64; Late 66Early: SOFA 10.8- APACHE2=12.3; Late: SOFA 11.6- APACHE2=14.0BIOCHEM: RIFLE criteria: RISK or pre-RISK criteriaRIFLE criteria: INJURY or FAILURE criteriaLOW NOQA=6Hosp mortality: Early 135/192(71%) died, Late 124/178 (70%) died (*P*=0.98)Vats, 2011 \[[@CR38]\]Retrospective cohortUSAJan1999 - Feb 2006Renal transplant, Pre-morbid ESRD on dialysis, RRT\<24h, insufficient dataMultisystem230NRNRAll patients mean = 66 NRNRTIME: Time from AKI to RRT \< 6 daysTime from AKI to RRT≥6dLOW NOQA=5OR for Late Mortality (\>6d) 11.66 (1.26-107.9) *P*=0.0305, Favors EarlyJi, 2011 \[[@CR36]\]Retrospective cohortChinaAp 2004 - Mar 2009Patients readmitted post discharge, Discharged against medical advice, Death \<24hrsPost cardiac surgery583424Early 64; Late 62Early: APACHE3=69.3; Late: APACHE3=88.2 *p*\<0.001TIME: Time from urine output \<0.5ml/kg/h to RRT\<12h; Mean oliguria to start of RRT 8.4hrsUrine output \<0.5ml/kg/h & Time to RRT\>12h post oliguria; Mean oliguria to start of RRT 21.5hrsLOW NOQA=6Hosp mortality: Early 3/34 (9%) died, Late 9/24 (37%); *p*=0.02 Favors EarlyShiao, 2012 \[[@CR41]\]Retrospective cohort 'NSARF' databaseTaiwanJan 2002 - Apr 2009Dialysis before surgery, ESRDSurgical648436212Early 62; Late 66; P=0.009Early: SOFA 11.4- APACHE2=12.7; Late: SOFA 11.3- APACHE2=12.8TIME: Time to development of tradtional RRT indications \< 3d; Mean time to start of RRT 1.4daysTraditional RRT indications AND start of RRT \> 3 days; Mean time to start of RRT 18daysLOW NOQA=6Hosp mortality: Early 236/436 (54%) died, Late 143/212 (67%) died; *P*=0.001 Favors EarlyChon, 2012 \[[@CR40]\]Retrospective cohortSouth KoreaApr 2009 - Oct 2010Liver cirrhosis, Pre existing chronicSepsis553619Early 63; Late 62Early: SOFA 13.5- APACHE2= 28.7; Late: SOFA 12- APACHE2=28.3TIME: Time to RIFLE 'Injury'/'Failure' \< 24hrs; Mean time to RRT=12.5hrsTime to RIFLE 'Injury'/'Failure' \> 24hrs; Mean time to RRT= 42.2hrsHIGH NOQA=728 d mortality: Early 7/36(38%), Late 9/19(47%); P=0.03 Favors EarlyBoussekey, 2012 \[[@CR39]\]Retrospective cohortFranceJan 2008 - Dec 2010Early trasfer to another unitMultisystem1106743Early 62; Late 66Early: SOFA: 11.1- SAPS2=70; Late: SOFA 8.8- SAPS2=57; *p*=0.002TIME: Time from RIFLE- 'Injury' to RRT \< 16hrs; Mean time to RRT=6hrsTime from RIFLE-'Injury' to RRT \> 16hrs; Mean time to RRT=64hrsLOW NOQA=728 d mortality: Early-28/67 (41%), Late- 28/43 (65%); *P*= 0.0425 Favors EarlySuzuki, 2013 \[[@CR43]\]Retrospective cohortJapanJan 2009 - Feb 2013\<18, RRT for ESRDSepsis, Cardiogenic Shock18952137All patients mean = 72 NRAll patients SAPS II Mean= 57BIOCHEM: RIFLE 'Risk'RIFLE 'Injury' or 'Failure'LOW NOQA=6Early: OR 0.361 (95 % CI 0.17--0.78); *P* = 0.009, Favors EarlyShum, 2013 \[[@CR43]\]Retrospective cohortChinaJan 2008 - Jun 2011Age\<18, Chronic dialysis, RRT prior to ICUSepsis1203189qEarly 74; Late 73Early: SOFA 12- APACHE4=119; Late: SOFA 13- APACHE4=133; *P*=0.011BIOCHEM: sRIFLE-'pre- Risk' or 'Risk' criteria; Mean time from ICU admit to RRT =20.7hrs, *P*=0.056sRIFLE 'Injury' or 'Failure' criteria; Mean time from ICU admit to RRT=10.8hrsLOW NOQA=628 d mortality: Early-15/31 died (48.4%), Late- 43/89 died (48.3%); *P*=0.994Tian, 2014 \[[@CR46]\]Retrospective cohortChinaNov 2009 - Dec 2011Age \< 12, Chronic renal disease, Terminal illness,0 Pre-admit CRRT, ICU stay \< 72hrsSepsis - AKIN 1492326Early 48; Control 54Early: SOFA 7.6- APACHE2=12.9; Control: SOFA 8.4- APACHE2=15.3BIOCHEM: AKIN 1 (Cr≥26.4μmol/L or \>150- 200% baseline & urine \<0.5cc/kg/h for \>6h)No RRT (Control): Patients refused CRRT for "personal reasons"LOW NOQA=628 d mortality: Early 5/23(22%) died, Control 11/26 (42%) died (NS)Sepsis - AKIN 2523121Early 54; Control 61Early: SOFA 9.3- APACHE2=19; Control SOFA 9.6- APACHE2=18.3AKIN 2 (Cr\>200-300% baseline & urine \<0.5cc/kg/h for \>12h)No RRT (Control): Patients refused CRRT for "personal reasons"28 d mortality: Early 12/31 (39%) died, Control 14/21 (67%) died; *P*\<0.05 Favors EarlySepsis - AKIN 3594613Early 50; Control 55Early SOFA 10- APACHE2=21.8; Control SOFA 11.2- APACHE2=20.5AKIN 3 (Cr≥354μmol/L or Cr\>300% baseline w/urine \<0.3cc/kg/h for 24h or anuria \>12h)No RRT (Control): Patients refused CRRT for "personal reasons"28 d mortality: Early 31/46(67%) died, Control 11/13(85%) died; NSSerpytis, 2014 \[[@CR45]\]Retrospective cohortLithuania2007-2011NRSepsis854243All patients mean = 72 NRNRTIME: Time from anuria to RRT \< 12hrsTime from anuria to RRT \> 12hrsLOW NOQA=5Mortality: Early 30/42 (71%) died, Late 39/43(91%) died; *p*=0.028; Favors EarlyGaudry, 2014 \[[@CR44]\]Retrospective cohortFranceJan 2004 - Nov 2011Age\<18, limitation in medical therapy, death\<24hrs, chronic renal insufficiency, RRT prior to ICU, kidney transplant, lithium toxicity, multiple myelomaSepsis20391112Early 65; Late 65Early: SOFA 9- SAPS2=60; Control SOFA 8- SAPS2=55, *P*\<0.01BIOCHEM: RRT criteria: Cr≥300μmol/L, Urea\>25mmol/L, K\>6.5mmol/L, pH\<7.2, Oliguria, Vol overload,No RRT initiated/Criteria not met for RRTLOW NOQA=5Hosp Mortality: Early 44/91(48%) died, Control (No RRT) 29/112 (26%) died; *P*\<0.001 Favors no RRTRetrospective TOTALS284114341177Pooled mortality: Early 714/1434 (50%), Late 732/1177 (62.2%); *n*=19*LEGEND*: *AKI* Acute kidney injury, *AKIN* Acute Kidney Injury Network, *APACHE* Acute Physiology and Chronic Health Evaluation, *Cr* Creatinine, *CRF* Chronic renal failure, *CRRT* Chronic renal replacement therapy, *eGFR* Estimated glomerular filtration rate, *EHV* Early High Volume, *ELV* Early Low Volume, *ESRD* End stage renal disease, *ICU* Intensive Care Unit, *LLV* Late Low Volume, *NOQA* Newcastle-Ottawa quality assessment, *NR* Not reported, *NSARF* National Taiwan University Hospital-Surgical ICU- Acute Renal Failure database, *RIFLE* Risk, Injury, Failure, Loss and End-stage, *RPGN* Rapidly progressive glomerularnephritis, *SAPS2* Squential Acute physiology Score, *SHARF* Stuivenberg Hospital Acute Renal Failure Score, *SOFA* Sequential Organ Failure Assessment, *UOP* Urine output

Primary outcome {#Sec9}
---------------

The observed pooled crude mortality rates varied significantly between the high- and low-quality studies. Among the high-quality studies, the pooled "early" RRT study group mortality rate was 34.6 % (192 of 555) compared with 40.2 % (196 of 487) in the pooled "late" RRT group. The low-quality studies demonstrated a pooled "early" RRT group mortality rate of 51.3 % (1871 of 3645) compared with 54.3 % (1486 of 2737) in the "late" RRT groups. The most frequently reported measurement of illness severity in the studies we analyzed was the Sequential Organ Failure Assessment (SOFA) score. The SOFA score has been correlated with critical care patient outcomes \[[@CR47], [@CR48]\], but it is not as robust as other scoring systems validated in predicting survival (e.g., Acute Physiology and Chronic Health Evaluation II \[APACHE2\] or Simplified Acute Physiology Score II \[SAPS2\]) \[[@CR49]\]. The mean weighted SOFA scores in the high-quality studies were 10.2 and 10.4 in the "early" and "late" groups, respectively. SOFA scores were reported for 78 % of patients in the high-quality studies. Among the high-quality studies, the SOFA score appeared to correspond with an APACHE2 score of approximately 20 or a SAPS2 score of approximately 53 when these additional illness severity metrics were reported by the principal investigators. Unfortunately, more detailed quantitative evaluation of illness severity using APACHE2 or SAPS2 scores was not possible, owing to heterogeneous reporting methods between investigators and a lack of sufficient data. SOFA scores were reported for 65 % of the patients in the studies assigned low-quality ratings. The mean weighted SOFA scores in the "early" and "late" groups among the low-quality studies were comparable to those for the high-quality studies at 10.0 and 9.2, respectively. No further comments can be made regarding illness severity scores among the low-quality studies, owing to lack of homogeneous and sufficient data. Illness severity scores for all studies are summarized in Table [1](#Tab1){ref-type="table"}.

Pooled analysis of the high-quality studies (*n* = 9) indicates no mortality benefit with "early" versus "late" RRT, with an OR of 0.665 (95 % CI 0.384--1.153, *p* = 0.146) (Fig. [1](#Fig1){ref-type="fig"}). The bulk of the data in support of "early" RRT rests in the pooled low-quality studies (*n* = 27), with an OR of 0.471 (95 % CI 0.343--0.649, *p* \< 0.001) (Fig. [2](#Fig2){ref-type="fig"}). Similarly to authors of previous meta-analyses, we found very high heterogeneity among studies on this topic. Heterogeneity was highest among the low-quality studies, reflected by a *Q* value of 163.8, *I*^2^ value of 84 %, and τ^2^ = 0.495 (*p* \< 0.001). Among the high-quality studies, there continued to be statistically significant heterogeneity, with a *Q* value of 29.1, *I*^2^ value of 72.5 %, and τ^2^ = 0.481 (*p* \< 0.001). Subgroup analysis of the high-quality studies according to ICU admission type and surgical \[[@CR14], [@CR16], [@CR21]\] versus mixed medical admissions \[[@CR7], [@CR12], [@CR15], [@CR17], [@CR35], [@CR40]\] demonstrated no significant subgroup mortality benefits associated with "early" RRT (see Additional file [4](#MOESM4){ref-type="media"}: Figure S3a and b for forest plots by ICU admission type). Subgroup analysis among the high-quality studies was also conducted using the definition of *early* according to time criteria (hours or days) versus biochemical parameters (i.e., rising creatinine, uremia, oliguria) (see Additional file [5](#MOESM5){ref-type="media"}: Figure S4a and b for forest plots by biochemical or time definition of *early*). There were no significant effects observed in pooled mortality trends in studies that defined *early* by time criteria rather than on the basis of biochemical parameters.Fig. 1Mortality forest plot of pooled analysis of high-quality studies (*n* = 9)Fig. 2Mortality forest plot pooled analysis of low-quality studies (*n* = 27)

Secondary outcomes {#Sec10}
------------------

The secondary outcomes analyzed included ICU LOS and hospital LOS. Five of the nine high-quality studies reported ICU LOS data \[[@CR12], [@CR16], [@CR17], [@CR35], [@CR40]\]. The mean weighted ICU LOS in the "early" group was 9.4 days (*n* = 351), compared with 10.8 days (*n* = 281) in the "late" group. None of the studies reported a significant finding with respect to ICU LOS and "early" RRT. Pooled analysis for ICU LOS also demonstrated no significant change in ICU LOS associated with "early" RRT, with a standard difference in the means of −0.035 (95 % CI −0.196 to 0.127, *p* = 0.674) using a fixed effects model (*Q* = 0.598, *p* = 0.963) (Fig. [3](#Fig3){ref-type="fig"}). Hospital LOS was reported in five of nine high-quality studies \[[@CR12], [@CR16], [@CR17], [@CR21], [@CR40]\]. The mean weighted hospital LOS in the "early" group was 19.3 days (*n* = 317), compared with 17.1 days (*n* = 266) in the "late" group. The pooled hospital LOS data do not reveal any significant difference in hospital LOS using a fixed effects model with a standard difference in the means of 0.040 (95 % CI −0.125 to 0.204, *p* = 0.638) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 3Forest plot of pooled analysis of standard difference of the means for intensive care unit length of stay (*n* = 5)Fig. 4Forest plot of pooled analysis of standard difference of the means for hospital length of stay (*n* = 5)

Discussion {#Sec11}
==========

Despite several studies having been conducted on this topic over the last 30 years, a clear answer regarding the optimal timing of RRT in critical illness remains elusive. Our analysis does not confirm the conclusions of previous meta-analyses on this topic. Four studies \[[@CR12], [@CR14], [@CR21], [@CR35]\] in the high-quality group were previously included in the meta-analysis by Karvellas et al. \[[@CR9]\], and only one study \[[@CR12]\] was included in the meta-analysis by Seabra et al*.* \[[@CR8]\]. The addition of four recently published studies \[[@CR15]--[@CR17], [@CR40]\] and one high-quality study that was not previously included in meta-analysis \[[@CR7]\] accounts for our results that differ from those of earlier authors. Our conclusions build on the concerns raised by both earlier meta-analyses that the results of cohort trials in favor of "early" RRT were not reproduced in methodologically more rigorous study designs (i.e., RCTs). In our further analysis we did not identify critical illness patient subgroups for whom "early" RRT might be more beneficial. Similarly, how one defines *early* (according to time or on the basis of biochemical characteristics) does not identify a survival advantage associated with "early" RRT compared with usual care. The optimal timing for initiation of RRT is not clarified on the basis of research evaluated to date.

The strength of our present analysis rests on our extensive literature search and strict classification according to study quality to limit risk of type I hypothesis testing error. Prior meta-analyses relied heavily on retrospective cohort study data that possessed incomplete preintervention data or preexisting significant differences in groups which predisposed the investigators to identify a survival difference attributed to "early" RRT that may have been accounted for by the preintervention population differences. We identified differences in the crude mortality rates between the high- and low-quality studies that are incompletely explained. The crude mortality rate differences may be explained by factors that are not adequately controlled for between the groups before the intervention of "early" versus "late" RRT (e.g., unreported regional institutional differences, variation in intensive care resources, institutional setting variability \[academic versus community\], or natural history variability of the diseases precipitating critical illness). In cohort trials, a difference in preintervention study groups indicates a critical methodological flaw that precludes deriving conclusions from their results. This is referred to as a type I error in hypothesis testing and may falsely attribute differences in outcomes to the study variable rather than the differences between cohorts that existed before analysis. Among high-quality studies, there was no survival advantage to "early" RRT with an OR of 0.665 (*p* = 0.146). Any inclusion of the low-quality study data would significantly pull the conclusion in favor of "early" RRT, which would represent fulfillment of a type I statistical hypothesis error. The strength of our work is that we vigorously guarded against this possibility.

Subgroup analysis of the high-quality studies did not reveal a survival benefit associated with either a surgical or medical critical care patient population. This conclusion remained the same regardless of whether *early* was defined by time or on the basis of biochemical parameters. Our secondary outcome analysis was limited by inconsistent and incomplete data reported across studies. Limited pooled analysis of the available data suggested that there was no significant effect on either ICU or hospital LOS associated with "early" RRT. Incomplete data does not permit us to evaluate additional secondary outcomes of interest (such as requirement for mechanical ventilation or rates of renal recovery) that might also be clinically relevant considerations factored into the decision to initiate RRT in critical illness.

By limiting our analysis to studies meeting high-quality criteria, we dismissed a large volume of research on this topic. A critique of our work is that we discarded studies for methodological shortcomings that others may feel should have been included. Most studies (*n* = 21) in the low-quality group were excluded for incomplete cohort data or significant preintervention differences between cohort groups. The decision to exclude these trials is less controversial than our decision to exclude cohort trials for an NOQA Scale rating less than 7 (*n* = 6). This is potentially controversial because the NOQA Scale has received criticism regarding its validity and applicability in meta-analysis cohort trial quality assessment \[[@CR50]\]. The NOQA Scale has received positive endorsement from some authors \[[@CR11]\], but detailed psychometric properties have not been published in peer-reviewed journals to date. Furthermore, our selection of an NOQA Scale rating less than 7 to identify low quality is arbitrary. Our rationale for selecting this cutoff was that it necessitates that at least one of the three NOQA Scale domains be seriously compromised, and we felt that this represented a significant bias predisposing the study results to committing a type I error pattern. Seabra et al. \[[@CR8]\] attempted to assign a quality score to trials (0 = lowest quality to 5 = best quality) to evaluate this domain, but their methodology for score assignment was obscure and was not able to be replicated or directly compared with our methods. In qualitative comparison, the study assigned their top score \[[@CR12]\] was included in our quantitative analysis; however, their second highest quality study \[[@CR13]\] was excluded due to lack of reported illness severity scores between groups. Including studies with methodological errors does not advance scientific understanding of this topic and has contributed to the discordant findings on it.

Early studies on this topic were small and may have overestimated an effect size associated with "early" RRT based on the small size of the study populations. An example of this problem is the Sugahara et al. study \[[@CR14]\], where 14-day mortality within the "early" group was 14 % (2 of 14), compared with 86 % (12 of 14) in the "late" group (*p* \< 0.01). While this study was included in our quantitative analysis, the magnitude of the mortality benefit reported in this trial associated with "early" RRT has not been reproduced by subsequent investigators, for reasons that are not clear. In our review of the ongoing trials on this topic registered with the NIH ([www.clinicalTrials.gov](http://www.clinical.trials.gov/)), we identified three trials \[[@CR51]--[@CR53]\] that may add to knowledge in this area. The methodology of all three active RCTs is roughly similar, with patients randomized from a point in time triggered by the development of biochemical renal injury reflected by a RIFLE grade of "failure" (at least one of rise in creatinine by minimum of 300 %, oliguria less than 0.3 ml/kg/h for 12 h, or anuria lasting more than 12 h). From this biochemical entry point, patients will be randomized to immediate initiation of RRT (goal time to RRT less than 12 h) or standard care (RRT initiated after failure of medical management to temporize metabolic derangements or volume overload). These study designs are similar to the design used by Wald et al. \[[@CR17]\], included in our analysis, that was able to separate an "early" group to mean time to RRT of 9.2 h and a "late" RRT group with a mean time to RRT of 32 h after biochemical inclusion criteria were met. Wald et al. \[[@CR17]\] did not identify a significant difference in mortality rates between their two groups (*p* = 0.74). These studies in process will add to the quantity of patients evaluated in this manner and will build on the availability of high-quality data on this topic. By clearly defining routine biochemical criteria associated with acute renal injury, they provide a practical method of renal injury assessment that can be determined by intensivists and nephrologists considering RRT.

Conclusions {#Sec12}
===========

The results of our meta-analysis contradict the findings reported by previous authors \[[@CR8], [@CR9]\], and we conclude that "early" initiation of RRT in critically ill patients with AKI does not improve survival. This conclusion is derived from the pooled high-quality trial data and excludes data from cohort trials where there were methodological shortcomings that predisposed them to find an effect misattributed to the intervention. Pooled analysis of secondary outcomes did not demonstrate a statistical reduction in ICU or hospital LOS. Additional well-designed RCTs will provide greater confidence in these conclusions as optimal patient care practices progress in critical care. Clinical triggers for the initiation of RRT to optimize patient outcomes have not been clearly identified by current research. Meanwhile, intensivists and nephrologists are encouraged to refrain from lowering their clinical thresholds for implementing RRT in critical care patients with acute renal injury.

Key messages {#Sec13}
============

High-quality trial data do not demonstrate improved survival using an "early" RRT approach in critical illness complicated by AKI.Lower-quality trial data demonstrate significantly higher mortality rates and form the basis for the bulk of support for "early" AKI.The optimal time to initiate RRT in critical illness remains undefined.A conservative approach to initiating RRT in critical illness is supported.
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AKI

:   acute kidney injury

AKIN

:   Acute Kidney Injury Network

AMA

:   against medical advice

APACHE2

:   Acute Physiology and Chronic Health Evaluation II

ARDS

:   acute respiratory distress syndrome

BUN

:   blood urea nitrogen

CKD

:   chronic kidney disease

Cr

:   creatinine

CRF

:   chronic renal failure

CRRT

:   continuous renal replacement therapy

EHV

:   early high volume hemofiltration

ELV

:   early low volume hemofiltration

eGFR

:   estimated glomerular filtration rate

ESRD

:   end-stage renal disease

ICU

:   intensive care unit
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:   illness severity score

LLV

:   late low volume hemofiltration

LOS

:   length of stay

NIH

:   National Institutes of Health

NOQA

:   Newcastle-Ottawa Quality Assessment

NR

:   not reported

NS

:   not significant

OR

:   odds ratio

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-Analyses

RCT

:   randomized controlled trial

RIFLE

:   risk, injury, failure, loss of function, and end-stage kidney disease

RPGN

:   rapidely progressive glomerulonephritis

RR

:   relative risk

RRT

:   renal replacement therapy

SAPS2

:   Simplified Acute Physiology Score II

SHARF

:   Stuivenberg Hospital Acute Renal Failure score below

SOFA

:   Sequential Organ Failure Assessment

sRIFLE

:   simple criteria for risk injury failure loss of function and end-stage kidney disease

UOP

:   urine output

NR

:   not reported
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